MSB 3.21% $1.13 mesoblast limited

NASDAQ hot!!!, page-226

  1. 446 Posts.
    lightbulb Created with Sketch. 464

    No @benelong I wasn’t thinking so much about the next gen sequencing tests as I was about the purpose of precision medicine, which the company’s trial selection criteria for different indications are increasingly honed and able to achieve ie. delivering treatments to the right patients at the right time. This approach, with its clear goal in mind, supports the health economics and speaks to the depth of the company’s understanding of when and with whom its treatment works best. It can certainly be described as very patient-centric.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.